Kura Oncology, Inc. is screened out under 1 exclusion reason spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Kura Oncology is a clinical-stage biopharmaceutical company that develops targeted small molecule cancer therapies. Its drug development pipeline involves preclinical and clinical research that requires animal testing as a standard regulatory step for safety and efficacy evaluation. The company’s SEC filings acknowledge that its development activities involve animals and commit to providing “humane care and treatment.” As a biotechnology firm focused on oncology, Kura’s core business model inherently relies on animal-based research to advance therapeutic candidates toward regulatory approval.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.